Novartis Oncology CEO Bruno Strigini to Retire
December 15 2017 - 1:48AM
Dow Jones News
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Friday that Bruno Strigini, chief
executive officer at Novartis Oncology, has decided to retire from
the company and the industry due to personal reasons.
Mr. Strigini will step back from the executive committee of
Novartis by Dec. 31. and complete the handover in early 2018, the
Swiss company said.
Chief Executive Joseph Jimenez thanked Mr. Strigini for his
contributions and achievements, citing the successful integration
of the GSK oncology-product portfolio that it acquired in 2015, and
which he led.
His successor will be announced in due time, it added.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
December 15, 2017 01:33 ET (06:33 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024